Previous 10 | Next 10 |
Shares of Cue Biopharma have tumbled some 75% since November 2021, as somewhat underwhelming data from slowly developing Phase 1 trials are at fault. The company’s Immuno-STAT platform is a novel approach to immuno-oncology that should reduce risks associated with systemic expo...
The U.S. FDA has accepted an Investigational New Drug application from Cue Biopharma (NASDAQ:CUE) for CUE-102, under investigation initially for gastric, pancreatic, ovarian and colon cancers. CUE-102 is designed to treat Wilms' Tumor 1 (WT1)-positive recurrent/metastatic cancers, an onco-fet...
Company to initiate Phase 1 dose escalation and expansion trial for the treatment of Wilms’ Tumor 1 (WT1) positive recurrent/metastatic cancers Starting dose of 1 mg/kg expected to reduce time and cost of dose escalation phase of trial, supporting development efficiency o...
Cue Biopharma press release (NASDAQ:CUE): Q1 GAAP EPS of -$0.44 misses by $0.02. Revenue of $1M (-35.5% Y/Y) misses by $1.92M. For further details see: Cue Biopharma GAAP EPS of -$0.44 misses by $0.02, revenue of $1M misses by $1.92M
BOSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, today reported first qua...
Shares of Cue Biopharma Inc. (NASDAQ:CUE) traded today at $35.20, eclipsing its 52-week high. So far today approximately 17.4 million shares have been exchanged, as compared to an average 30-day volume of 573,000 shares. There is potential upside of 5.8% for shares of Cue Biopharma Inc. ...
Clinical-stage biotech, Cue Biopharma (CUE +7.1%), is trading higher for the fourth straight session on Tuesday after its director Aaron Fletcher disclosed an insider purchase worth millions of dollars. According to a Form 4 filed with the U.S. Securities and Exchange Commission (SEC) on Mond...
Gainers: Sunshine Biopharma (SBFM) +181%. Nano-X Imaging (NNOX) +15%. Arcus Biosciences (RCUS) +13%. Cue Biopharma (CUE) +11%. Dermata Therapeutics (DRMA) +6%. Losers: IMARA (IMRA) -35%. GBS (GBS) -15%. Precipio (PRPO) -13%. Cassava Sciences (SAVA) -10%...
CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced to...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
News, Short Squeeze, Breakout and More Instantly...
Prioritizing autoimmune programs aims to focus upon near-term and intermediate value creation potential, while retaining oncology programs as promising clinical data continues to mature - Company anticipates annualized capital and workforce requirements to be reduced by approximately 25...
Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+ head and neck squamous cell carcinoma (HNSCC) treated with CUE-101 and KEYTRUDA ® (pembrolizumab) Median overall survival (mOS) of 20.8 months in second...
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced that it will participate in two investor confe...